Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from University of Illinois in the area of breast cancer published
June 25th, 2009
According to recent research published in the journal Molecular Cancer Research, "Several breast cancer tumor models respond to estradiol (E-2) by undergoing apoptosis, a phenomenon known to occur in clinical breast cancer. Before the application of tamoxifen as an endocrine therapy, high-dose E-2 or diethystilbesterol treatment was successfully used, albeit with unfavorable side effects." "It is now recognized that such an approach may be a potential endocrine therapy option. We have explored the mechanism of E-2-induced tumor regression in our T47D:A18/PKC alpha tumor model that exhibits autonomous growth, tamoxifen resistance, and E-2-induced tumor regression....
Source: Women's Health Weekly (2009-06-25)
|
